http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0621588-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_caec7099b724bb45d2518787825aab94 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2006-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecc6e8fe906746f7ebbb98c4ce5b7ca3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b893e8ef34926ef2da9d4c10f1e60290 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c8b5fe4832c6c5def5c79ac99c913a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c11afefa1e3cdf11c7a600b7d5c90f1c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71ecb7b40e6705c3e8796d065a09d23e |
| publicationDate | 2011-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0621588-A2 |
| titleOfInvention | agent for the prevention and treatment of prostatic hyperplasia comprising the pyrazolpyrimidinone compound |
| abstract | AGENT FOR THE PREVENTION AND TREATMENT OF PROSTATIC HYPERPLASIA UNDERSTANDING THE PIRAZOLPYRIMIDINONE COMPOUND. The present invention relates to an agent for the prevention and treatment of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) associated with BPH and a relaxant for relaxing urethral smooth muscle or prostate smooth muscle , comprising a pyrazolopyrimidinone compound as an effective ingredient. The agent according to the present invention is able to deliver nitric oxides by inhibiting the PDE-5 activity that breaks down c-GMP, and the nitric oxides supplied relax the urethral smooth muscle or the prostate smooth muscle to decrease pressure intraurethral (IUP), thus treating BPH and the LUTS associated with BPH. In addition, the time required to reach maximum blood concentration is shorter, and the half-life is longer than that of the other PDE-5 inhibitors, thereby reducing the frequency of administration. Furthermore, the agent of the invention, because it causes few side effects, can be used effectively as a safe drug. |
| priorityDate | 2006-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 151.